165 related articles for article (PubMed ID: 38627373)
21. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
22. Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.
Saeed M; van Brakel M; Zalba S; Schooten E; Rens JA; Koning GA; Debets R; Ten Hagen TL
Int J Nanomedicine; 2016; 11():955-75. PubMed ID: 27022262
[TBL] [Abstract][Full Text] [Related]
23. Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
Chen JL; Stewart-Jones G; Bossi G; Lissin NM; Wooldridge L; Choi EM; Held G; Dunbar PR; Esnouf RM; Sami M; Boulter JM; Rizkallah P; Renner C; Sewell A; van der Merwe PA; Jakobsen BK; Griffiths G; Jones EY; Cerundolo V
J Exp Med; 2005 Apr; 201(8):1243-55. PubMed ID: 15837811
[TBL] [Abstract][Full Text] [Related]
24. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
Denkberg G; Klechevsky E; Reiter Y
J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy.
Sanderson JP; Crowley DJ; Wiedermann GE; Quinn LL; Crossland KL; Tunbridge HM; Cornforth TV; Barnes CS; Ahmed T; Howe K; Saini M; Abbott RJ; Anderson VE; Tavano B; Maroto M; Gerry AB
Oncoimmunology; 2020; 9(1):1682381. PubMed ID: 32002290
[TBL] [Abstract][Full Text] [Related]
26. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
[TBL] [Abstract][Full Text] [Related]
27. TCR-like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus-transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants.
Lai J; Choo JAL; Tan WJ; Too CT; Oo MZ; Suter MA; Mustafa FB; Srinivasan N; Chan CEZ; Lim AGX; Zhong Y; Chan SH; Hanson BJ; Gascoigne NRJ; MacAry PA
Sci Rep; 2017 Aug; 7(1):9923. PubMed ID: 28855662
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4
Wang L; Matsumoto M; Akahori Y; Seo N; Shirakura K; Kato T; Katsumoto Y; Miyahara Y; Shiku H
Mol Ther; 2024 Mar; 32(3):734-748. PubMed ID: 38243600
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.
Dao T; Pankov D; Scott A; Korontsvit T; Zakhaleva V; Xu Y; Xiang J; Yan S; de Morais Guerreiro MD; Veomett N; Dubrovsky L; Curcio M; Doubrovina E; Ponomarev V; Liu C; O'Reilly RJ; Scheinberg DA
Nat Biotechnol; 2015 Oct; 33(10):1079-86. PubMed ID: 26389576
[TBL] [Abstract][Full Text] [Related]
30. Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.
Audehm S; Glaser M; Pecoraro M; Bräunlein E; Mall S; Klar R; Effenberger M; Albers J; Bianchi HO; Peper J; Yusufi N; Busch DH; Stevanović S; Mann M; Antes I; Krackhardt AM
Front Immunol; 2019; 10():1485. PubMed ID: 31316521
[TBL] [Abstract][Full Text] [Related]
31. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells.
Watanabe K; Tsukahara T; Toji S; Saitoh S; Hirohashi Y; Nakatsugawa M; Kubo T; Kanaseki T; Kameshima H; Terui T; Sato N; Torigoe T
Cancer Sci; 2019 Jan; 110(1):40-51. PubMed ID: 30375705
[TBL] [Abstract][Full Text] [Related]
32. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC; Border EC; Vieira JF; Pumphrey NJ
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
[TBL] [Abstract][Full Text] [Related]
33. CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins.
Jost C; Darowski D; Challier J; Pulko V; Hanisch LJ; Xu W; Mössner E; Bujotzek A; Klostermann S; Umana P; Kontermann RE; Klein C
MAbs; 2020; 12(1):1840709. PubMed ID: 33136521
[TBL] [Abstract][Full Text] [Related]
34. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody.
Bernardeau K; Gouard S; David G; Ruellan AL; Devys A; Barbet J; Bonneville M; Chérel M; Davodeau F
Eur J Immunol; 2005 Oct; 35(10):2864-75. PubMed ID: 16163672
[TBL] [Abstract][Full Text] [Related]
35. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
36. Conformational dimorphism of self-peptides and molecular mimicry in a disease-associated HLA-B27 subtype.
Rückert C; Fiorillo MT; Loll B; Moretti R; Biesiadka J; Saenger W; Ziegler A; Sorrentino R; Uchanska-Ziegler B
J Biol Chem; 2006 Jan; 281(4):2306-16. PubMed ID: 16221670
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal and recombinant antibodies with T cell receptor-like reactivity.
Ziegler A; Coulie PG; Uchańska-Ziegler B
Recent Results Cancer Res; 2007; 176():229-41. PubMed ID: 17607930
[TBL] [Abstract][Full Text] [Related]
38. Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR.
Denkberg G; Cohen CJ; Reiter Y
J Immunol; 2001 Jul; 167(1):270-6. PubMed ID: 11418659
[TBL] [Abstract][Full Text] [Related]
39. Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells.
Lee MN; Meyerson M
Sci Immunol; 2021 Jan; 6(55):. PubMed ID: 33483338
[TBL] [Abstract][Full Text] [Related]
40. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.
Chames P; Willemsen RA; Rojas G; Dieckmann D; Rem L; Schuler G; Bolhuis RL; Hoogenboom HR
J Immunol; 2002 Jul; 169(2):1110-8. PubMed ID: 12097420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]